{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:20:51Z","timestamp":1792441251875,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Acute myeloid leukemia (AML), the most common leukemia in adults, exhibits immune escape characteristics like solid tumors. The expression of indoleamine 2,3-dioxygenase 1 (IDO1), a well-recognized immune checkpoint, has been detected in AML blast cells and is associated with poor clinical outcome. Although an imbalance of B cell subpopulations exists in AML patients\u2019 bone marrow microenvironment, the role of B cells and their interaction with IDO1 in AML have yet to be elucidated. Herein, with bioinformatic analysis, we found the close correlations between IDO1 expression and survival and B cell subpopulation proportions in AML patients. Further, our investigation into IDO1 expression and activity, B cell subpopulation proportions and immunosuppressive interleukin-10 (IL-10) level in AML cells and clinical samples revealed significant findings. Using a co-culture system of healthy human PBMCs and AML cell lines, we demonstrated that high IDO1 expression in AML cells could alter the proportions of total B, regulatory B and memory B cells, and increased the level of IL-10. Finally, with the IDO1 inhibitor RY103 designed by our laboratory, we found that IDO1 inhibition had good anti-leukemic effect and restored the abnormal proportions of B cell subpopulations in AML mice. Our study is the first to reveal the modulation of IDO1 on B cell subpopulations in AML, making a significant breakthrough in understanding the immune escape mechanisms of AML. Application of IDO1 inhibitor, such as RY103, targeting the imbalance of B cell subpopulations can lead to innovative treatments for AML.<\/jats:p>","DOI":"10.1186\/s43556-025-00262-x","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T02:42:27Z","timestamp":1744771347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Indoleamine 2,3-dioxygenase 1 alters the proportions of B cell subpopulations in the microenvironment of acute myeloid leukemia"],"prefix":"10.1186","volume":"6","author":[{"given":"Yu","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-shuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"issue":"2","key":"262_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264\u201378. https:\/\/doi.org\/10.1016\/j.cell.2012.06.023.","journal-title":"Cell"},{"issue":"7","key":"262_CR2","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441. https:\/\/doi.org\/10.1038\/bcj.2016.50.","journal-title":"Blood Cancer J"},{"issue":"3","key":"262_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502\u201326. https:\/\/doi.org\/10.1002\/ajh.26822.","journal-title":"Am J Hematol"},{"key":"262_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.651687","volume":"12","author":"G Wells","year":"2021","unstructured":"Wells G, Kennedy PT, Dahal LN. Investigating the role of indoleamine 2,3-dioxygenase in acute myeloid leukemia: A systematic review. Front Immunol. 2021;12: 651687. https:\/\/doi.org\/10.3389\/fimmu.2021.651687.","journal-title":"Front Immunol"},{"issue":"5","key":"262_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","volume":"122","author":"F Mussai","year":"2013","unstructured":"Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122(5):749\u201358. https:\/\/doi.org\/10.1182\/blood-2013-01-480129.","journal-title":"Blood"},{"issue":"13","key":"262_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-1426-1-13","volume":"1","author":"RM Teague","year":"2013","unstructured":"Teague RM, Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer. 2013;1(13):1. https:\/\/doi.org\/10.1186\/2051-1426-1-13.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"262_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2219554","volume":"28","author":"J Fang","year":"2023","unstructured":"Fang J, Zhang R, Lin X, Xu Y, Huang K, Saw PE. Aberrant expression of T cell activation markers and upregulation of Tregs in bone marrow and peripheral blood in acute myeloid leukemia patients. Hematology. 2023;28(1): 2219554. https:\/\/doi.org\/10.1080\/16078454.2023.2219554.","journal-title":"Hematology"},{"issue":"5","key":"262_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","volume":"102","author":"H Sun","year":"2015","unstructured":"Sun H, Li Y, Zhang ZF, Ju Y, Li L, Zhang BC, et al. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol. 2015;102(5):579\u201386. https:\/\/doi.org\/10.1007\/s12185-015-1865-2.","journal-title":"Int J Hematol"},{"issue":"1","key":"262_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12964-023-01282-2","volume":"21","author":"M Bakhtiyari","year":"2023","unstructured":"Bakhtiyari M, Liaghat M, Aziziyan F, Shapourian H, Yahyazadeh S, Alipour M, et al. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways. Cell Commun Signal. 2023;21(1):252. https:\/\/doi.org\/10.1186\/s12964-023-01282-2.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"262_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten M, Nollen EAA, Rohrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18(5):379\u2013401. https:\/\/doi.org\/10.1038\/s41573-019-0016-5.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"262_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13046-021-01847-4","volume":"40","author":"Y Yao","year":"2021","unstructured":"Yao Y, Liang H, Fang X, Zhang S, Xing Z, Shi L, et al. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. J Exp Clin Cancer Res. 2021;40(1):60. https:\/\/doi.org\/10.1186\/s13046-021-01847-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"262_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106132","volume":"177","author":"X Fang","year":"2022","unstructured":"Fang X, Guo L, Xing Z, Shi L, Liang H, Li A, et al. IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10. Pharmacol Res. 2022;177: 106132. https:\/\/doi.org\/10.1016\/j.phrs.2022.106132.","journal-title":"Pharmacol Res"},{"key":"262_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.molimm.2018.09.011","volume":"103","author":"J Zhang","year":"2018","unstructured":"Zhang J, Han X, Hu X, Jin F, Gao Z, Yin L, et al. IDO1 impairs NK cell cytotoxicity by decreasing NKG2D\/NKG2DLs via promoting miR-18a. Mol Immunol. 2018;103:144\u201355. https:\/\/doi.org\/10.1016\/j.molimm.2018.09.011.","journal-title":"Mol Immunol"},{"issue":"4","key":"262_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.20020121","volume":"196","author":"G Frumento","year":"2002","unstructured":"Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196(4):459\u201368. https:\/\/doi.org\/10.1084\/jem.20020121.","journal-title":"J Exp Med"},{"issue":"5","key":"262_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI31178","volume":"117","author":"DH Munn","year":"2007","unstructured":"Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147\u201354. https:\/\/doi.org\/10.1172\/JCI31178.","journal-title":"J Clin Invest"},{"key":"262_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/253191","volume":"2015","author":"S Trabanelli","year":"2015","unstructured":"Trabanelli S, Lecciso M, Salvestrini V, Cavo M, Ocadlikova D, Lemoli RM, et al. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J Immunol Res. 2015;2015: 253191. https:\/\/doi.org\/10.1155\/2015\/253191.","journal-title":"J Immunol Res"},{"issue":"2","key":"262_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","volume":"13","author":"RB Holmgaard","year":"2015","unstructured":"Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, et al. Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep. 2015;13(2):412\u201324. https:\/\/doi.org\/10.1016\/j.celrep.2015.08.077.","journal-title":"Cell Rep"},{"key":"262_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00151","volume":"9","author":"L Hornyak","year":"2018","unstructured":"Hornyak L, Dobos N, Koncz G, Karanyi Z, Pall D, Szabo Z, et al. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol. 2018;9: 151. https:\/\/doi.org\/10.3389\/fimmu.2018.00151.","journal-title":"Front Immunol"},{"issue":"2","key":"262_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1535-7163.MCT-09-0628","volume":"9","author":"HK Koblish","year":"2010","unstructured":"Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 2010;9(2):489\u201398. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0628.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"262_CR20","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","volume":"115","author":"X Liu","year":"2010","unstructured":"Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520\u201330. https:\/\/doi.org\/10.1182\/blood-2009-09-246124.","journal-title":"Blood"},{"issue":"21","key":"262_CR21","doi-asserted-by":"publisher","first-page":"8321","DOI":"10.1021\/jm401195n","volume":"56","author":"S Yang","year":"2013","unstructured":"Yang S, Li X, Hu F, Li Y, Yang Y, Yan J, et al. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013;56(21):8321\u201331. https:\/\/doi.org\/10.1021\/jm401195n.","journal-title":"J Med Chem"},{"issue":"20","key":"262_CR22","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.1021\/acs.jmedchem.9b01079","volume":"62","author":"D Yang","year":"2019","unstructured":"Yang D, Zhang S, Fang X, Guo L, Hu N, Guo Z, et al. N-Benzyl\/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase. J Med Chem. 2019;62(20):9161\u201374. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01079.","journal-title":"J Med Chem"},{"issue":"1","key":"262_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-019-0103-4","volume":"5","author":"L Du","year":"2020","unstructured":"Du L, Xing Z, Tao B, Li T, Yang D, Li W, et al. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway. Signal Transduct Target Ther. 2020;5(1):10. https:\/\/doi.org\/10.1038\/s41392-019-0103-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"262_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070870","volume":"16","author":"Z Xing","year":"2024","unstructured":"Xing Z, Li X, He ZNT, Fang X, Liang H, Kuang C, et al. IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma. Pharmaceutics. 2024;16(7): 870. https:\/\/doi.org\/10.3390\/pharmaceutics16070870.","journal-title":"Pharmaceutics"},{"issue":"5","key":"262_CR25","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1002\/mco2.555","volume":"5","author":"H Liang","year":"2024","unstructured":"Liang H, Zhan J, Chen Y, Xing Z, He ZNT, Liu Y, et al. Tryptophan deficiency induced by indoleamine 2,3-dioxygenase 1 results in glucose transporter 1-dependent promotion of aerobic glycolysis in pancreatic cancer. MedComm (2020). 2024;5(5):e555. https:\/\/doi.org\/10.1002\/mco2.555.","journal-title":"MedComm (2020)"},{"issue":"2","key":"262_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.leu.2404485","volume":"21","author":"A Curti","year":"2007","unstructured":"Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia. 2007;21(2):353\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2404485.","journal-title":"Leukemia"},{"issue":"3","key":"262_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.leukres.2008.06.014","volume":"33","author":"S Corm","year":"2009","unstructured":"Corm S, Berthon C, Imbenotte M, Biggio V, Lhermitte M, Dupont C, et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients\u2019 sera by HPLC and is inducible by IFN-gamma. Leuk Res. 2009;33(3):490\u20134. https:\/\/doi.org\/10.1016\/j.leukres.2008.06.014.","journal-title":"Leuk Res"},{"issue":"1","key":"262_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12032-010-9459-6","volume":"28","author":"NM El Kholy","year":"2011","unstructured":"El Kholy NM, Sallam MM, Ahmed MB, Sallam RM, Asfour IA, Hammouda JA, et al. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells. Med Oncol. 2011;28(1):270\u20138. https:\/\/doi.org\/10.1007\/s12032-010-9459-6.","journal-title":"Med Oncol"},{"issue":"8","key":"262_CR29","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.18632\/oncotarget.1504","volume":"5","author":"V Folgiero","year":"2014","unstructured":"Folgiero V, Goffredo BM, Filippini P, Masetti R, Bonanno G, Caruso R, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget. 2014;5(8):2052\u201364. https:\/\/doi.org\/10.18632\/oncotarget.1504.","journal-title":"Oncotarget"},{"issue":"12","key":"262_CR30","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3324\/haematol.13113","volume":"93","author":"ME Chamuleau","year":"2008","unstructured":"Chamuleau ME, van de Loosdrecht AA, Hess CJ, Janssen JJ, Zevenbergen A, Delwel R, et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica. 2008;93(12):1894\u20138. https:\/\/doi.org\/10.3324\/haematol.13113.","journal-title":"Haematologica"},{"issue":"5","key":"262_CR31","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3109\/10428194.2014.953150","volume":"56","author":"K Fukuno","year":"2015","unstructured":"Fukuno K, Hara T, Tsurumi H, Shibata Y, Mabuchi R, Nakamura N, et al. Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. Leuk Lymphoma. 2015;56(5):1398\u2013405. https:\/\/doi.org\/10.3109\/10428194.2014.953150.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"262_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/10428194.2015.1041388","volume":"57","author":"R Mabuchi","year":"2016","unstructured":"Mabuchi R, Hara T, Matsumoto T, Shibata Y, Nakamura N, Nakamura H, et al. High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. Leuk Lymphoma. 2016;57(1):92\u20138. https:\/\/doi.org\/10.3109\/10428194.2015.1041388.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"262_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/bloodadvances.2021004878","volume":"6","author":"S Ragaini","year":"2022","unstructured":"Ragaini S, Wagner S, Marconi G, Parisi S, Sartor C, Nanni J, et al. An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia. Blood Adv. 2022;6(1):87\u201399. https:\/\/doi.org\/10.1182\/bloodadvances.2021004878.","journal-title":"Blood Adv"},{"key":"262_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01918","volume":"8","author":"M Lecciso","year":"2017","unstructured":"Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E, et al. ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. Front Immunol. 2017;8: 1918. https:\/\/doi.org\/10.3389\/fimmu.2017.01918.","journal-title":"Front Immunol"},{"issue":"8","key":"262_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/10245332.2015.1106814","volume":"21","author":"I Mansour","year":"2016","unstructured":"Mansour I, Zayed RA, Said F, Latif LA. Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia. Hematology. 2016;21(8):447\u201353. https:\/\/doi.org\/10.1080\/10245332.2015.1106814.","journal-title":"Hematology"},{"issue":"12","key":"262_CR36","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3324\/haematol.2010.025924","volume":"95","author":"A Curti","year":"2010","unstructured":"Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D, et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica. 2010;95(12):2022\u201330. https:\/\/doi.org\/10.3324\/haematol.2010.025924.","journal-title":"Haematologica"},{"issue":"19","key":"262_CR37","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1158\/0008-5472","volume":"76","author":"P Tsou","year":"2016","unstructured":"Tsou P, Katayama H, Ostrin EJ, Hanash SM. The Emerging Role of B Cells in Tumor Immunity. Cancer Res. 2016;76(19):5597\u2013601. https:\/\/doi.org\/10.1158\/0008-5472.","journal-title":"Cancer Res"},{"issue":"3","key":"262_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2991\/chi.k.200712.001","volume":"2","author":"M Goswami","year":"2020","unstructured":"Goswami M, Lindblad KE, Ramraj R, Dagur PK, Thompson J, McCoy JP, et al. B cell deficiency in patients with relapsed and refractory acute myeloid leukemia. Clin Hematol Int. 2020;2(3):125\u20138. https:\/\/doi.org\/10.2991\/chi.k.200712.001.","journal-title":"Clin Hematol Int"},{"issue":"1","key":"262_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12967-017-1252-2","volume":"15","author":"M Goswami","year":"2017","unstructured":"Goswami M, Prince G, Biancotto A, Moir S, Kardava L, Santich BH, et al. Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy. J Transl Med. 2017;15(1):155. https:\/\/doi.org\/10.1186\/s12967-017-1252-2.","journal-title":"J Transl Med"},{"issue":"11","key":"262_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259197","volume":"16","author":"H Bolouri","year":"2021","unstructured":"Bolouri H, Ries R, Pardo L, Hylkema T, Zhou W, Smith JL, et al. A B-cell developmental gene regulatory network is activated in infant AML. PLoS ONE. 2021;16(11): e0259197. https:\/\/doi.org\/10.1371\/journal.pone.0259197.","journal-title":"PLoS ONE"},{"key":"262_CR41","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.12659\/MSM.915556","volume":"25","author":"Y Lv","year":"2019","unstructured":"Lv Y, Wang H, Liu Z. The role of regulatory B cells in patients with acute myeloid leukemia. Med Sci Monit. 2019;25:3026\u201331. https:\/\/doi.org\/10.12659\/MSM.915556.","journal-title":"Med Sci Monit"},{"key":"262_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886225","volume":"13","author":"LMF Merlo","year":"2022","unstructured":"Merlo LMF, Peng W, Mandik-Nayak L. Impact of IDO1 and IDO2 on the B Cell Immune Response. Front Immunol. 2022;13: 886225. https:\/\/doi.org\/10.3389\/fimmu.2022.886225.","journal-title":"Front Immunol"},{"issue":"5","key":"262_CR43","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.4049\/jimmunol.1402854","volume":"195","author":"R Shinde","year":"2015","unstructured":"Shinde R, Shimoda M, Chaudhary K, Liu H, Mohamed E, Bradley J, et al. B Cell-Intrinsic IDO1 Regulates Humoral Immunity to T Cell-Independent Antigens. J Immunol. 2015;195(5):2374\u201382. https:\/\/doi.org\/10.4049\/jimmunol.1402854.","journal-title":"J Immunol"},{"issue":"22","key":"262_CR44","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1301689.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"262_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10875-016-0263-8","volume":"36","author":"A Floudas","year":"2016","unstructured":"Floudas A, Amu S, Fallon PG. New Insights into IL-10 Dependent and IL-10 Independent Mechanisms of Regulatory B Cell Immune Suppression. J Clin Immunol. 2016;36(Suppl 1):25\u201333. https:\/\/doi.org\/10.1007\/s10875-016-0263-8.","journal-title":"J Clin Immunol"},{"issue":"4","key":"262_CR46","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity. 2015;42(4):607\u201312. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.005.","journal-title":"Immunity"},{"issue":"1","key":"262_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1086\/315214","volume":"181","author":"CA Gogos","year":"2000","unstructured":"Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000;181(1):176\u201380. https:\/\/doi.org\/10.1086\/315214.","journal-title":"J Infect Dis"},{"issue":"1","key":"262_CR48","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41598-018-19460-5","volume":"8","author":"H Abdelrasoul","year":"2018","unstructured":"Abdelrasoul H, Werner M, Setz CS, Okkenhaug K, Jumaa H. PI3K induces B-cell development and regulates B cell identity. Sci Rep. 2018;8(1):1327. https:\/\/doi.org\/10.1038\/s41598-018-19460-5.","journal-title":"Sci Rep"},{"issue":"8","key":"262_CR49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2319364121","volume":"121","author":"K Wang","year":"2024","unstructured":"Wang K, Zhang W, Yi L, Zhao M, Li PY, Fu MH, et al. The impact of age and number of mutations on the size of clonal hematopoiesis. Proc Natl Acad Sci U S A. 2024;121(8): e2319364121. https:\/\/doi.org\/10.1073\/pnas.2319364121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"262_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008318","volume":"12","author":"S Guo","year":"2024","unstructured":"Guo S, Mohan GS, Wang B, Li T, Daver N, Zhao Y, et al. Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia. J Immunother Cancer. 2024;12(2): e008318. https:\/\/doi.org\/10.1136\/jitc-2023-008318.","journal-title":"J Immunother Cancer"},{"key":"262_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.18632\/oncoscience.540","volume":"8","author":"K Syama","year":"2021","unstructured":"Syama K, Hassan EM, Zou S. Advances in culture methods for acute myeloid leukemia research. Oncoscience. 2021;8:82\u201390. https:\/\/doi.org\/10.18632\/oncoscience.540.","journal-title":"Oncoscience"},{"issue":"12","key":"262_CR52","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41417-023-00675-2","volume":"30","author":"CY Tseng","year":"2023","unstructured":"Tseng CY, Fu YH, Ou DL, Lu JW, Hou HA, Lin LI. Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K\/AKT\/mTOR signaling and suppression of mitochondrial biogenesis. Cancer Gene Ther. 2023;30(12):1691\u2013701. https:\/\/doi.org\/10.1038\/s41417-023-00675-2.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"262_CR53","doi-asserted-by":"publisher","DOI":"10.5812\/ijpr-140507","volume":"22","author":"A Ranjbar","year":"2023","unstructured":"Ranjbar A, Soltanshahi M, Taghiloo S, Asgarian-Omran H. Glucose metabolism in acute myeloid leukemia cell line is regulated via combinational PI3K\/AKT\/mTOR pathway inhibitors. Iran J Pharm Res. 2023;22(1): e140507. https:\/\/doi.org\/10.5812\/ijpr-140507.","journal-title":"Iran J Pharm Res"},{"issue":"12","key":"262_CR54","doi-asserted-by":"publisher","first-page":"e49756","DOI":"10.15252\/embr.201949756","volume":"21","author":"A Iacono","year":"2020","unstructured":"Iacono A, Pompa A, De Marchis F, Panfili E, Greco FA, Coletti A, et al. Class IA PI3Ks regulate subcellular and functional dynamics of IDO1. EMBO Rep. 2020;21(12):e49756. https:\/\/doi.org\/10.15252\/embr.201949756.","journal-title":"EMBO Rep"},{"issue":"9","key":"262_CR55","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/leu.2012.87","volume":"26","author":"E Lion","year":"2012","unstructured":"Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia. 2012;26(9):2019\u201326. https:\/\/doi.org\/10.1038\/leu.2012.87.","journal-title":"Leukemia"},{"issue":"7","key":"262_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002968","volume":"9","author":"S Herbrich","year":"2021","unstructured":"Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, et al. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. J Immunother Cancer. 2021;9(7): e002968. https:\/\/doi.org\/10.1136\/jitc-2021-002968.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"262_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-021-00265-0","volume":"9","author":"R Guo","year":"2021","unstructured":"Guo R, L\u00fc M, Cao F, Wu G, Gao F, Pang H, et al. Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res. 2021;9(1):15. https:\/\/doi.org\/10.1186\/s40364-021-00265-0.","journal-title":"Biomark Res"},{"issue":"7","key":"262_CR58","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773\u201382. https:\/\/doi.org\/10.1038\/s41587-019-0114-2.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"262_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3): 100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.","journal-title":"Innovation (Camb)"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00262-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00262-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00262-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T02:42:28Z","timestamp":1744771348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00262-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00262-x","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Approval No. 82230006), and all individuals provided informed consent for inclusion of their tissue in this study. Moreover, animal study was approved by the Animal Ethics Committee of Fudan University and performed in compliance with ARRIVE guidelines (Approval No. JS-006, March 4th, 2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0k, e and f.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}